EUVIMEDEUVIMED entdecken
Open Access

Comment on Kutz et al. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes. Diabetes Care 2023;46:2004–2014

Giuseppe Maltese iD, Alan J Sinclair

Diabetes Care · 2024

DOI: 10.2337/dc23-2420 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Care, 2024. Verfasst von Giuseppe Maltese und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes and Endocrinology, Epsom and St. Helier University Hospitals, Surrey, U.K. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Dipeptidyl-Peptidase IV Inhibitors, Frailty. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Findings from a recent cohort study published in Diabetes Care (1), which included > 740,000 individuals with type 2 diabetes (T2D) aged $ 65 years, demonstrated that both sodium glucose cotrans-porter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RAs) were associated with smaller numbers of cardiovascular events and death than di-peptidyl peptidase 4 inhibitors (DPP-4i), with the largest bene fi ts being seen among frail people. Adverse events that affected frailer individuals were not more common with SGLT2i or GLP-1RAs than with DPP-4i (1). We wish to highlight that despite this robust evidence, there is still diffuse hesi-tancy to prescribe SGLT2i and/or GLP-1RAs to frail subjects, possibly due to the fear of side effects and the lack of guidance on their use. In a cross-sectional study that evaluated 103,790 people with T2D and cardiovascular disease and a median age of 71 years (range 64 – 79), divided in three groups according to the frailty status (nonfrail, moderately frail, and severely frail) and followed up for a median time of 4.5 years, most frail individuals were less likely to receive SGLT2i and GLP-1RAs

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsFrailtyHumansGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Substanzen

Sodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Diabetes and Endocrinology, Epsom and St. Helier University Hospitals, Surrey, U.K.
  • School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London, U.K.
  • Foundation for Diabetes Research in Older People (fDROP), Droitwich Spa, London, U.K.

ORCID-Profile: Giuseppe Maltese

Zitieren

APA

Maltese, G., & Sinclair, A. J. (2024). Comment on Kutz et al. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes. Diabetes Care 2023;46:2004–2014. Diabetes Care. https://doi.org/10.2337/dc23-2420

Vancouver

Maltese G, Sinclair AJ. Comment on Kutz et al. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes. Diabetes Care 2023;46:2004–2014. Diabetes Care. 2024. doi:10.2337/dc23-2420

BibTeX
@article{Maltese2024,
  author = {Maltese, Giuseppe and Sinclair, Alan J},
  title = {Comment on Kutz et al. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes. Diabetes Care 2023;46:2004–2014},
  journal = {Diabetes Care},
  year = {2024},
  doi = {10.2337/dc23-2420}
}
Kostenlos starten →